Novel tyrosine kinase signaling pathways: Implications in vascular remodeling

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 2, 2012, Pages 122-127

  Batchu, Sri N ^a   Korshunov, Vyacheslav A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

receptor tyrosine kinase; signal transduction; vascular remodeling

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; G PROTEIN COUPLED RECEPTOR; GROWTH ARREST SPECIFIC PROTEIN 6; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; R 428; SIGNAL PEPTIDE; SOMATOMEDIN C RECEPTOR; TELATINIB; TRANSFORMING GROWTH FACTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR;

ATHEROSCLEROSIS; CANCER THERAPY; CAPILLARY DENSITY; DOWNSTREAM PROCESSING; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MECHANICAL STRESS; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIDE EFFECT; TUMOR GROWTH; VASCULAR DISEASE;

BLOOD VESSELS; HUMANS; HYPERTENSION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, SOMATOMEDIN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84857044453     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283503ce9     Document Type: Review

References (46)

1. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19:5548-5557.
2. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141:1117-1134.
3. Berk BC. Vascular smooth muscle growth: Autocrine growth mechanisms. Physiol Rev 2001; 81:999-1030. (Pubitemid 32606665)
4. Gavi S, Shumay E, Wang HY, Malbon CC. G-protein-coupled receptors and tyrosine kinases: Crossroads in cell signaling and regulation. Trends Endocrinol Metab 2006; 17:48-54.
5. Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 2003; 284:31-53. (Pubitemid 36331965)
6. Birukov KG. Cyclic stretch, reactive oxygen species, and vascular remodeling. Antioxid Redox Signal 2009; 11:1651-1667.
7. Schreier B, Dohler M, Rabe S, et al. Consequences of epidermal growth factor receptor (ErbB1) loss for vascular smooth muscle cells from mice with targeted deletion of ErbB1. Arterioscler Thromb Vasc Biol 2011; 31:1643-1652.
8. Singh NK, Wang D, Kundumani-Sridharan V, et al. 15-Lipoxygenase-1- enhanced Src-Janus kinase 2-signal transducer and activator of transcription 3 stimulation and monocyte chemoattractant protein-1 expression require redox-sensitive activation of epidermal growth factor receptor in vascular wall remodeling. J Biol Chem 2011; 286:22478-22488.
9. Griol-Charhbili V, Fassot C, Messaoudi S, et al. Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 2011; 57:238-244. This study demonstrates that aldosterone increases vascular contractility and not arterial thickening via activation of EGFR-dependent signaling.
10. Takaguri A, Kimura K, Hinoki A, et al. A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature. Hypertension 2011; 57:841-845. This report shows that ADAM17 stimulates vascular growth by activation of EGFR signals.
11. Takaguri A, Shirai H, Kimura K, et al. Caveolin-1 negatively regulates a metalloprotease-dependent epidermal growth factor receptor transactivation by angiotensin II. J Mol Cell Cardiol 2011; 50:545-551. These findings indicate that Cav-1 is a negative regulator for AngII-mediated ADAM17 release and activated EGFR in vascular cells.
12. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16:143-163.
13. Liu G, Hitomi H, Hosomi N, et al. Mechanical stretch augments insulininduced vascular smooth muscle cell proliferation by insulin-like growth factor-1 receptor. Exp Cell Res 2011; 317:2420-2428.
14. Ma Y, Zhang L, Peng T, et al. Angiotensin II stimulates transcription of insulinlike growth factor I receptor in vascular smooth muscle cells: Role of nuclear factor-kappaB. Endocrinology 2006; 147:1256-1263. (Pubitemid 43244358)
15. Song H, Mowbray AL, Sykes MC, Jo H. Emerging role of IGF-1R in stretchinduced neointimal hyperplasia in venous grafts. Arterioscler Thromb Vasc Biol 2007; 27:1679-1681. (Pubitemid 47207161)
16. Wu X, Cheng J, Li P, et al. Mechano-sensitive transcriptional factor Egr-1 regulates insulin-like growth factor-1 receptor expression and contributes to neointima formation in vein grafts. Arterioscler Thromb Vasc Biol 2010; 30:471-476. This study demonstrates that transcriptional factor Egr-1 is responsible for increases in expression of IGF1R in response to mechanical stress.
17. Zahradka P, Storie B, Wright B. IGF-1 receptor transactivation mediates Src-dependent cortactin phosphorylation in response to angiotensin II. Can J Physiol Pharmacol 2009; 87:805-812.
18. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22:1276-1312. (Pubitemid 351717519)
19. Shaw A, Xu Q. Biomechanical stress-induced signaling in smooth muscle cells: An update. Curr Vasc Pharmacol 2003; 1:41-58.
20. Ma YH, Ling S, Ives HE. Mechanical strain increases PDGF-B and PDGF beta receptor expression in vascular smooth muscle cells. Biochem Biophys Res Commun 1999; 265:606-610.
21. Higuchi S, Ohtsu H, Suzuki H, et al. Angiotensin II signal transduction through the AT1 receptor: Novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 2007; 112:417-428. (Pubitemid 46587457)
22. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: Role of angiotensin II. Exp Physiol 2005; 90:449-455. (Pubitemid 40980144)
23. Chen PY, Simons M, Friesel R. FRS2 via fibroblast growth factor receptor 1 is required for platelet-derived growth factor receptor beta-mediated regulation of vascular smooth muscle marker gene expression. J Biol Chem 2009; 284:15980-15992.
24. Mendelson K, Swendeman S, Saftig P, Blobel CP. Stimulation of plateletderived growth factor receptor beta (PDGFRbeta) activates ADAM17 and promotes metalloproteinase-dependent cross-talk between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling pathways. J Biol Chem 2010; 285:25024-25032. This study demonstrates a cross-talk between PDGFRb and EGFR via stimulation of ADAM17 activity.
25. Guo X, Nie L, Esmailzadeh L, et al. Endothelial and smooth muscle-derived neuropilin-like protein regulates platelet-derived growth factor signaling in human vascular smooth muscle cells by modulating receptor ubiquitination. J Biol Chem 2009; 284:29376-29382.
26. Koch S, Tugues S, Li X, et al. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011; 437:169-183.
27. Jaffe IZ, Newfell BG, Aronovitz M, et al. Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest 2010; 120: 3891-3900. Authors reported vascular-specific aldosterone-dependent activation of VEGFR-1 pathway in response to arterial injury.
28. Storkebaum E, Ruiz de Almodovar C, Meens M, et al. Impaired autonomic regulation of resistance arteries in mice with low vascular endothelial growth factor or upon vascular endothelial growth factor trap delivery. Circulation 2010; 122:273-281.
29. Pang J, Hoefen R, Pryhuber GS, et al. G-protein-coupled receptor kinase interacting protein-1 is required for pulmonary vascular development. Circulation 2009; 119:1524-1532.
30. Stockmann C, Kerdiles Y, Nomaksteinsky M, et al. Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis. Proc Natl Acad Sci USA 2010; 107:4329-4334.
31. Farkas L, Farkas D, Ask K, et al. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 2009; 119:1298-1311.
32. Zhang J, Silva T, Yarovinsky T, et al. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ Res 2010; 107:408-417. This report suggests that VEGFR-1 is expressed on T lymphocytes and augments T cell recruitment to the vessel wall during neointima formation.
33. Mac Gabhann F, Popel AS. Systems biology of vascular endothelial growth factors. Microcirculation 2008; 15:715-738.
34. Nagata K, Ohashi K, Nakano T, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996; 271:30022-30027. (Pubitemid 26389640)
35. Melaragno MG, Wuthrich DA, Poppa V, et al. Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats. Circ Res 1998; 83:697-704. (Pubitemid 28462783)
36. Melaragno MG, Cavet ME, Yan C, et al. Gas6 inhibits apoptosis in vascular smooth muscle: Role of Axl kinase and Akt. J Mol Cell Cardiol 2004; 37:881-887. (Pubitemid 39222079)
37. Cavet ME, Smolock EM, Ozturk OH, et al. Gas6-Axl receptor signaling is regulated by glucose in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28:886-891. (Pubitemid 351544103)
38. Cavet ME, Smolock EM, Menon P, et al. Gas6-Axl pathway: The role of redoxdependent association of Axl with nonmuscle myosin IIB. Hypertension 2010; 56:105-111. This report suggests that ROS-dependent posttranslational modification of nonmuscle myosin heavy chain-IIB lead to Axl binding and migration of VSMCs.
39. Smolock EM, Korshunov VA. Pharmacological inhibition of Axl affects smooth muscle cell functions under oxidative stress. Vasc Pharmacol 2010; 53:185-192. Small molecule inhibitors of Axl are effective in blocking ligand-independent (oxidative stress) activation of VSMCs.
40. Holland SJ, Pan A, Franci C, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010; 70:1544-1554. This is the first report effectiveness of small molecule inhibitor of Axl (R428) in mouse models of tumorigenesis in vivo.
41. Lijnen HR, Christiaens V, Scroyen L. Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice. J Pharmacol Exp Ther 2011; 337:457-464.
42. Thorp E, Cui D, Schrijvers DM, et al. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe/ mice. Arterioscler Thromb Vasc Biol 2008; 28:1421-1428.
43. Lutgens E, Tjwa M, Garcia de Frutos P, et al. Genetic loss of Gas6 induces plaque stability in experimental atherosclerosis. J Pathol 2008; 216:55-63.
44. Thorp E, Vaisar T, Subramanian M, et al. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase C{delta}, and p38 mitogen-Activated protein kinase (MAPK). J Biol Chem 2011; 286:33335-33344. This study demonstrates ROS-dependent mechanisms by which ADAM17 cleaves Mertk in immune cells.
45. Steeghs N, Gelderblom H, Roodt JO, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008; 14:3470-3476.
46. Mayer EL, Dallabrida SM, Rupnick MA, et al. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension 2011; 58:85-92. This study provides NO-dependent mechanism of increase in blood pressure after treatment with vandetanib.